Influenza virus vaccine composition and methods of use

US7785603B2 · kind B2 · utility

Assignee

• Vical Incorporated · US

Inventors

• Catherine J. Luke · Frederick, US
• Adrian Vilalta · San Diego, US
• Mary Kopke Wloch · San Diego, US
• Thomas G. Evans · New York, US
• Andrew Geall · Littleton, US
• Gretchen S. Jimenez · San Diego, US

Key dates

• Filing date: Mar 9, 2007
• Grant date: Aug 31, 2010
• Expiry date: May 20, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/16151
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.